Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization

Journal of Clinical Investigation

Volumn 111, Issue 12, 2003, Pages 1835-1842

  Kondo, Tatsuya ^a   Vicent, David ^a   Suzuma, Kiyoshi ^a   Yanagisawa, Masashi ^b   King, George L ^a   Holzenberger, Martin ^c   Kahn, C Ronald ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c HÔPITAL SAINT ANTOINE   (France)

^d JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; INSULIN; INSULIN RECEPTOR; NITRIC OXIDE SYNTHASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN; ENDOTHELIAL CELL GROWTH FACTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LYMPHOKINE; NOS3 PROTEIN, HUMAN; NOS3 PROTEIN, MOUSE; SIGNAL PEPTIDE; VASCULOTROPIN A;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; RETINOPATHY; ANIMAL; ANOXIA; C57BL MOUSE; DBA MOUSE; DISEASE MODEL; GENETICS; HUMAN; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA BLOOD VESSEL; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; ANOXIA; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; RETINAL VESSELS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0041743158     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317455     Document Type: Article

References (48)

1. Moss, S.E., Klein, R., and Klein, B.E. 1998. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 105:998-1003.
2. Koya, D., and King, G.L. 1998. Protein kinase C activation and the development of diabetic complications. Diabetes. 47:859-866.
3. Katzman, G.H. 1996. Retinopathy of prematurity: is suppression of neovascularization achievable? J. Pediatr. 129:618-619.
4. Aiello, L.P., et al. 1998. Diabetic retinopathy. Diabetes Care. 21:143-156.
5. Hamanaka, T., Akabane, N., Yajima, T., Takahashi, T., and Tanabe, A. 2001. Retinal ischemia and angle neovascularization in proliferative diabetic retinopathy. Am. J. Ophthalmol. 132:648-658.
6. Lu, M., et al. 1999. Insulin-induced vascular endothelial growth factor expression in retina. Invest. Ophthalmol. Vis. Sci. 40:3281-3286.
7. Poulaki, V., et al. 2002. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1α and VEGF. J. Clin. Invest. 109:805-815. doi:10.1172/JCI200213776.
8. Jozkowicz, A., et al. 1999. Nitric oxide mediates the mitogenic effects of insulin and vascular endothelial growth factor but not of leptin in endothelial cells. Acta Biochim. Pol. 46:703-715.
9. Ding, Y., Vaziri, N.D., Coulson, R., Kamanna, V.S., and Roh, D.D. 2000. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am. J. Physiol. Endocrinol. Metab. 279:E11-E17.
10. Kuboki, K., et al. 2000. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 101:676-681.
11. Oliver, F.J., et al. 1991. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J. Biol. Chem. 266:23251-23256.
12. Desideri, G., Ferri, C., Bellini, C., De Mattia, G., and Santucci, A. 1997. Effects of ACE inhibition on spontaneous and insulin-stimulated endothelin-1 secretion: in vitro and in vivo studies. Diabetes. 46:81-86.
13. Cardillo, C., et al. 1999. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation. 100:820-825.
14. Smith, L.E., et al. 1994. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35:101-111.
15. Henricsson, M., Nilsson, A., Janzon, L., and Groop, L. 1997. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet. Med. 14:123-131.
16. Lauritzen, T., Frost-Larsen, K., Larsen, H.W., and Deckert, T. 1985. Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes. 3(Suppl.):74-79.
17. Dahl-Jorgensen, K., Brinchmann-Hansen, O., Hanssen, K.F., Sandvik, L., and Aagenaes, O. 1985. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br. Med. J. (Clin. Res. Ed.) 290:811-815.
18. Roysarkar, T.K., Gupta, A., Dash, R.J., and Dogra, M.R. 1993. Effect of insulin therapy on progression of retinopathy in noninsulin-dependent diabetes mellitus. Am. J. Ophthalmol. 115:569-574.
19. Smith, L.E., et al. 1999. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat. Med. 5:1390-1395.
20. Vicent, D., et al. 2003. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J. Clin. Invest. 111:1373-1380. doi:10.1172/JCI200315211.
21. Page, C., Rose, M., Yacoub, M., and Pigott, R. 1992. Antigenic heterogeneity of vascular endothelium. Am. J. Pathol. 141:673-683.
22. Lutty, G.A., McLeod, D.S., Merges, C., Diggs, A., and Plouet, J. 1996. Localization of vascular endothelial growth factor in human retina and choroid. Arch. Ophthalmol. 114:971-977.
23. Cunha-Vaz, J. 1998. Lowering the risk of visual impairment and blindness. Diabet. Med. 4(Suppl.):S47-S50.
24. Shichiri, M., Kishikawa, H., Ohkubo, Y., and Wake, N. 2000. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2(Suppl.):B21-B29.
25. Cheatham, B., et al. 1994. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell Biol. 14:4902-4911.
26. Mendez, R., Myers, M.G., Jr., White, M.F., and Rhoads, R.E. 1996. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol. Cell Biol. 16:2857-2864.
27. Aiello, L.P., et al. 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487.
28. Miller, J.W., Adamis, A.P., and Aiello, L.P. 1997. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab. Rev. 13:37-50.
29. Simpson, D.A., et al. 1999. Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia. Biochem. Biophys. Res. Commun. 262:333-340.
30. Ozaki, H., et al. 2000. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 156:697-707.
31. Stone, J., and Maslim, J. 1997. Mechanisms of retinal angiogenesis. Prog. Retin. Eye Res. 16:157-181.
32. Ten, V.S., and Pinsky, D.J. 2002. Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. Curr. Opin. Crit. Care. 8:242-250.
33. Semenza, G.L. 2000. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 88:1474-1480.
34. Yan, S.F., et al. 1999. Hypoxia-associated induction of early growth response-1 gene expression. J. Biol. Chem. 274:15030-15040.
35. Lo, L.W., et al. 2001. Endothelial exposure to hypoxia induces Egr-1 expression involving PKCalpha-mediated Ras/Raf-1/ERK1/2 pathway. J. Cell Physiol. 188:304-312.
36. Rees, D.D., Palmer, R.M., and Moncada, S. 1989. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl. Acad. Sci. U. S. A. 86:3375-3378
37. Murad, F., et al. 1992. The nitric oxide-cyclic GMP signal transduction pathway in vascular smooth muscle preparations and other tissues. Jpn. J. Pharmacol. 58(Suppl.):150P-157P.
38. Fukumura, D., et al. 2001. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. U. S. A. 98:2604-2609.
39. Ono, Y., Ono, H., Matsuoka, H., Fujimori, T., and Frohlich, E.D. 1999. Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension. 34:609-616.
40. Adachi, K., et al. 1998. Inhibition of NMDA receptors and nitric oxide synthase reduces ischemic injury of the retina. Eur. J. Pharmacol. 350:53-57.
41. Brooks, S.E., et al. 2001. Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. Invest. Ophthalmol. Vis. Sci. 42:222-228.
42. Tadesse, M., Yan, Y., Yossuck, P., and Higgins, R.D. 2001. Captopril improves retinal neovascularization via endothelin-1. Invest. Ophthalmol. Vis. Sci. 42:1867-1872.
43. Salani, D., et al. 2000. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol. 157:1703-1711.
44. McLeod, D.S., Brownstein, R., and Lutty, G.A. 1996. Vaso-obliteration in the canine model of oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 37:300-311.
45. Takagi, C., et al. 1996. Endothelin-1 action via endothelin receptors is a primary mechanism modulating retinal circulatory response to hyperoxia. Invest. Ophthalmol. Vis. Sci. 37:2099-2109.
46. Hermann, C., Assmus, B., Urbich, C., Zeiher, A.M., and Dimmeler, S. 2000. Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20:402-409.
47. 1998. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch. Ophthalmol. 116:874-886.
48. Attia, N., et al. 1999. Changes in free insulin-like growth factor-1 and leptin concentrations during acute metabolic decompensation in insulin withdrawn patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 84:2324-2328.